Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 3rd International Conference and Expo on Biopharmaceutics and Biologic Drugs Singapore City, Singapore.

Day 1 :

  • Pharmacological Sciences

Session Introduction

Bimal Roy Krishna

Touro University Nevada,USA

Title: Current treatment guidelines for osteoporosis
Biography:

Dr. Krishna currently holds the position of Professor& Director of Pharmacology and Chair-SPC at the College of Osteopathic Medicine-Touro University Nevada. He has been Adjunct Professor of Pharmacology for Kaplan Medical for the past 12 years where he has been actively involved in Step1 USMLE and COMLEX reviews throughout the USA and in Mexico, Caribbean, Poland, India, UAE, South America and Saudi Arabia. In addition he is an Adjunct and Visiting Professor at various other national and international institutions.

Abstract:

Osteoporosis, a metabolic bone disease is associated with progressive reduction of bone density leading to bone fragility and increased susceptibility to fractures. In the United States it affects 10 million of the population, aged 50 or greater of which 2 million are men, The incidence and prevalence is much higher in post-menopausal women.It is an asymptomatic condition, often diagnosed after a fracture typically of the hip, spine, pelvis or wrist. It is therefore essential that high risk patient be identified early in order to commence prophylactic measures. Diagnosis of osteoporosis measures bone mineral density particularly in the hip and lumbar spine and is done via dual-energy x-ray absorptiometry (DEXA scan). Thereafter T-scores are used to assess BMD and fracture risks.

Biography:

Wael k. Ali is affiliated to General Secretary of EMROpharm forum-international pharmaceutical federation (FIP) and President of Egyptian organization of pharmacy, Egypt. Wael k. Ali is a recipient of many awards and grants for his valuable contributions and discoveries in major area of subject research. His international experience includes various programs, contributions and participation in different countries for diverse fields of study.

Abstract:

A fundamental goal of pharmacy transformation is to enhance patient and pharmacist experience by allowing a flexible bidirectional healthcare exchange. Success lies in a pharmacist’s ability to create pharmacy interactions that place patients top of mind. The pharmacy becomes patients oriented in parallel with medicine oriented. The complete change or transformation of the pharmacy depends on two pillars First pillar is Pharmacy Education and second pillar is pharmacy workforce. Transforming pharmacy in Middle East countries specially, Egypt, We will focus on change and transforming the pharmacy in Egypt, Middle East countries and African countries as well in education, workforce, advocacy, regulations and practitioners. In Egypt around 300,000 licensed pharmacists, 53 schools of pharmacy and more than 75,000 pharmacy students. That makes all early career pharmacists eager to learn more and more about the new pharmacy specialties.

Biography:

Christian Schäfer is a Full-Professor at the Department of Business Administration at Baden- Württemberg Cooperative State University Mannheim (DHBW) Germany. He teaches quantitative Methods, simulation in strategic forecasting and market research in healthcare. His research interests are in the fields of quantification of uncertainty, Patient-Behaviour- Modelling, and Partial Least Squares Structural Equation Modeling (PLS-SEM). Christian also runs special forecast-simulation and market research projects for the Pharmaceutical Industry. Prior to taking this role in 2015, Christian covered different Management and Director positions in Marketing, Competitive Intelligence, Strategic Forecasting and PM- Strategy within two International Pharmaceutical Company for 8 years. Christian earned a Diploma (Master) in Economics, a Master of Business Administration (MBA) degree from University of Gävle, Sweden and received his PhD (Dr.) from the Department of Business Administration and Economics at Johannes Gutenberg-University Mainz, Germany, where he worked 4 years as a research assistant. He published more than 25 articles and 4 Books.

 

Abstract:

Uncertainty is by definition an unpreventable aspect of all projects. In the pharmaceutical industry development projects for a new chemical / biological entity (NCE / NBE) are generally associated with low probabilities of success compared to other industries. Assessing the sweet spots of favourable risk-return-relationship in milestone decision making of pipeline projects – also under a portfolio point of view – is tricky but nicely achievable. At start of development, a project’s rate of success is only 4% to 7%, the time span of a project from start of development to the potential launch of a product being 10 years or even more. Thus, effective management of commercial risk and uncertainty becomes tremendously important. The Pharmaceutical Benchmark Forum in the United States collected industry-wide historical data on the drug development process (Harpum, 2010). The result of this research shows that the total project development costs for a NCE which reaches the market are in the range of $ 1 billion. The actual costs of a successful project are usually significantly lower, but every successful project needs to cover the costs of multiple other projects which did not in the end reach the market.

Biography:

Prof. Dr. Gholamhossein Sodeifian (1971) graduated in chemical engineering (M.S) from University of Tehran, in 1997 and received his doctorate (Ph.D), in polymer engineering from Tarbiat Modares University, Tehran, in 2002. Prof. Sodeifian is currently academic member of Chemical Engineering Department of University of Kashan. His research group focused on extraction of essential and seed oils, solubility measurement of solid medicines, and micro- and nanoparticle formation of pharmaceutical materials in supercritical carbon dioxide (SCCO2) via various methods. He has also developed, for the first time in the world, a new and efficient technique for nanoparticle formation, i.e., ultrasonic assisted rapid expansion of supercritical solution into a liquid solvent (US-RESOLV). He has published more than 83 ISI scientific papers and several books. Furthermore, he has developed Sodeifian’s model for drugs solubility. Prof. Sodeifian has been assigned and included in the worlds’ top 2% of scientists list in 2021 and 2022.

Abstract:

Hepato-Cellular Carcinoma (HCC) is the fifth prevalent malignant tumor having the third rank in the global mortality chart. Sorafenib tosylate (SFB) is approved as the first anticancer drug for the treatment of HCC. According to the Biopharmaceutical Classification Scheme (BCS), SFB belongs to class II compounds that indicate a very poor solubility in the aqueous solution at different pH values from pH=1.2 to pH=7.4 (slow dissolution rate within the gastrointestinal tracts) and high permeability from the gastrointestinal lumen. The drug has low oral bioavailability (8.43%); consequently, high dose treatment is necessary which may cause the systemic toxicity [Figure 1]. Nanotechnology based novel drug delivery systems are applied to design the systems with improved biocompatibility and biodegradability which can deliver the drug molecule efficiently and safely to the target tissue thus decrease the side effects, especially for drugs with narrow therapeutic index or cytotoxic effects.

Biography:

Rafid A. Doulab is a lecturer in physiology field for more than 15 years and he worked on developing his skills in the imaging techniques. The passion and interest did not stop to this extent, as a new era and a major shift began after the Corona pandemic through manufacture a transport medium for the COVID-19 virus, which was considered the first of its kind in Iraq and the Middle East, which was invested by the Iraqi Ministry of Health and with direct support from the World Health Organization. The discoveries and patents were carried out. He was able to record access to the readings within one year and then he began the second phase of the overlapping of data acquisition applications in the field of physiology and its relationship to pharmaceutical sciences he was able to register three patents in America related with dosage form as well as application of electron microscope in pharmacopeia. Now he focuses in developing solutions to reduce environmental contamination resulting from environmental pollution in oil field.

Abstract:

Elemental Impurities in Pharmaceuticals industry is indispensable to ensure of pharmaceuticals safety, for 24 elements Although atomic absorption and inductively coupled plasma are used in the U.S Pharmacopeia and the European Pharmacopoeia, FESEM with energy dispersive spectrometers can be applied as an alternative analysis method for quantitative and qualitative results for a variety of elements without chemical pretreatment, unlike other techniques. This technique characterizes by shortest time, with less contamination, no reagent consumption and generation of minimal residue or waste as well as sample preparations time limiting, with minimal analysis error. Simple dilution for powder or direct analysis for liquid, we analyzed the usefulness of Energy Dispersive Spectrophotometry (EDS) method in testing with Field Emission Scanning Electron Microscopy (FESEM, SUPRA 55 Carl Zeiss Germany) with X-ray energy dispersion (XFlash 6-10 detector Germany). The samples analyzed directly without coating by applied 5 µ of known concentrated diluted sample on carbon stub with accelerated voltage according to sample thickness, the result for this spot was in atomic percentage and by Avogadro converted factor the final results will be in microgram.

Biography:

Nihaya Odeh, a master's student at Birzeit University in Pharmaceutical Technology, I am very interested in the topics covered in this program, specializing in health care services, holds a Bachelor's degree in Pharmacy with a very good grade from An-Najah National University. Having worked in drug sales and community pharmacies for four years, I am interested in research on drug analytics and how manufacturing factors affect drugs. My long-term goal is to get Ph.D. To share my experience with other professional colleges and learn more from them so that I can use my knowledge to make better drugs. I am interested to participate in the conference in order to be able to share my article with discuss it for more developments, I am very pleased to improve and expand my knowledge and skills, and hopefully, this conference engaging me in insightful discussions with others about the latest happenings in the field.

Abstract:

Background: Sodium valproate has anticonvulsant activity and is structurally different to conventional antiepileptic drugs. The problem with valproic acid is the lack of a chromophore, which means that gas chromatography is the sole assay methodology. The introduction of benzoyl and phenyl groups to the molecule is a useful derivatisation, which enables the creation of detectable chromophores for HPLC analysis for pharmaceutical dosages as well as biological systems.

Methodology: Sodium valproate was derivatised by the addition of a chromophore to its structure by introducing a methyl benzoyl or a phenyl group. Trichlorophenol and 2-hydroxyacetophenone were used to introduce phenyl and benzoyl groups to valproic acid, respectively. The reaction used was estrification reaction using coupling agents. An analytical method was then developed and validated using reverse-phase HPLC. The method was validated for parameters like linearity, range, accuracy precision and robustness